{"protocolSection":{"identificationModule":{"nctId":"NCT03964415","orgStudyIdInfo":{"id":"CR108604"},"secondaryIdInfos":[{"id":"2018-003666-13","type":"EUDRACT_NUMBER"},{"id":"VAC89220HPX3002","type":"OTHER","domain":"Janssen Vaccines & Prevention B.V."},{"id":"HVTN 706","type":"OTHER","domain":"HIV Vaccine Trials Network (HVTN)"},{"id":"2018","type":"NIH","link":"https://reporter.nih.gov/quickSearch/2018"}],"organization":{"fullName":"Janssen Vaccines & Prevention B.V.","class":"INDUSTRY"},"briefTitle":"A Study of Heterologous Vaccine Regimen of Adenovirus Serotype 26 Mosaic4 Human Immunodeficiency Virus(Ad26.Mos4.HIV), Adjuvanted Clade C gp140 and Mosaic gp140 to Prevent HIV-1 Infection Among Cis-gender Men and Transgender Individuals Who Have Sex With Cis-gender Men and/or Transgender Individuals","officialTitle":"A Multi-center, Randomized, Double-blind, Placebo-controlled Phase 3 Efficacy Study of a Heterologous Vaccine Regimen of Ad26.Mos4.HIV and Adjuvanted Clade C gp140 and Mosaic gp140 to Prevent HIV-1 Infection Among Cis-gender Men and Transgender Individuals Who Have Sex With Cis-gender Men and/or Transgender Individuals","acronym":"MOSAICO"},"statusModule":{"statusVerifiedDate":"2024-06","overallStatus":"COMPLETED","expandedAccessInfo":{"hasExpandedAccess":false},"startDateStruct":{"date":"2019-10-31","type":"ACTUAL"},"primaryCompletionDateStruct":{"date":"2023-08-10","type":"ACTUAL"},"completionDateStruct":{"date":"2023-08-10","type":"ACTUAL"},"studyFirstSubmitDate":"2019-05-24","studyFirstSubmitQcDate":"2019-05-24","studyFirstPostDateStruct":{"date":"2019-05-28","type":"ACTUAL"},"resultsFirstSubmitDate":"2024-07-04","resultsFirstSubmitQcDate":"2024-07-04","resultsFirstPostDateStruct":{"date":"2024-07-31","type":"ACTUAL"},"lastUpdateSubmitDate":"2024-07-04","lastUpdatePostDateStruct":{"date":"2024-07-31","type":"ACTUAL"}},"sponsorCollaboratorsModule":{"responsibleParty":{"type":"SPONSOR"},"leadSponsor":{"name":"Janssen Vaccines & Prevention B.V.","class":"INDUSTRY"}},"oversightModule":{"oversightHasDmc":true,"isFdaRegulatedDrug":true,"isFdaRegulatedDevice":false},"descriptionModule":{"briefSummary":"The purpose of this study is to evaluate the vaccine efficacy (VE) of a heterologous vaccine regimen utilizing Ad26.Mos4.HIV and aluminum phosphate-adjuvanted Clade C gp140 and Mosaic gp140 for the prevention of HIV-1 infection in HIV-1 seronegative cis-gender men and transgender individuals having sex with cis-gender men and/or transgender individuals.","detailedDescription":"Human immunodeficiency virus type 1 (HIV-1) is a retrovirus that, if left untreated, can progress to acquired immunodeficiency syndrome (AIDS), a condition in which the immune system is severely compromised, leading to life-threatening conditions. Ad26.Mos4.HIV is a tetravalent vaccine composed of Ad26.Mos1.Gag-Pol, Ad26.Mos2.Gag-Pol, Ad26.Mos1.Env, and Ad26.Mos2S.Env. Clade C and Mosaic gp140 HIV bivalent vaccine contains: Clade C gp140, HIV-1 Env gp140 of Clade C, Mosaic gp140, HIV-1 Env gp140, and aluminum phosphate adjuvant. Evidences showed that a combination of vaccination with Ad26.Mos.HIV followed by Ad26.Mos.HIV together with Clade C gp140 protein in aluminum phosphate adjuvant led to highest level of protection observed so far with this vaccine concept. Study comprises of a screening period of 45 days, a 12-month vaccination period and a follow-up period of at least 18 months after fourth vaccination (until Month 30) in participants who remain HIV-1 negative or up to 6 months after diagnosis of HIV-1 infection in participants who become HIV-1 infected. Participants who completed their Month 30 visit will be followed for HIV infection, medically-attended adverse event (MAAEs) and serious adverse events until the end of study (Month 30). Primary analysis of vaccine efficacy will evaluate the number of HIV-1 infections in the vaccine group compared to number of HIV-1 infections in the placebo group between Month 7 and Month X (with 24\\<=X\\<=30) in per-protocol population."},"conditionsModule":{"conditions":["Healthy"]},"designModule":{"studyType":"INTERVENTIONAL","phases":["PHASE3"],"designInfo":{"allocation":"RANDOMIZED","interventionModel":"PARALLEL","primaryPurpose":"PREVENTION","maskingInfo":{"masking":"TRIPLE","whoMasked":["PARTICIPANT","CARE_PROVIDER","INVESTIGATOR"]}},"enrollmentInfo":{"count":3900,"type":"ACTUAL"}},"armsInterventionsModule":{"armGroups":[{"label":"Group1:Ad26.Mos4.HIV,Clade C and Mosaic gp140 bivalent vaccine","type":"EXPERIMENTAL","description":"Participants will receive adenovirus serotype 26.Mosaic 4.human immunodeficiency virus (Ad26.Mos4.HIV) via intramuscular (IM) injection into the deltoid muscle at months 0 (Day 1) and 3 (preferably the deltoid of the non-dominant upper arm) and, Ad26.Mos4.HIV together with Clade C and Mosaic gp140 HIV bivalent vaccine IM into the deltoid muscle at Months 6 and 12 (different deltoid for each injection).","interventionNames":["Biological: Ad26.Mos4.HIV","Biological: Clade C and Mosaic gp140 HIV bivalent vaccine"]},{"label":"Group 2: Placebo","type":"PLACEBO_COMPARATOR","description":"Participants will receive placebo into the deltoid muscle on Months 0 (Day 1), 3 (1 injection), 6 and 12 (2 injections).","interventionNames":["Biological: Placebo"]}],"interventions":[{"type":"BIOLOGICAL","name":"Ad26.Mos4.HIV","description":"Participants will receive Ad26.Mos4.HIV via IM injection into the deltoid muscle at months 0 (Day 1), 3, 6 and 12.","armGroupLabels":["Group1:Ad26.Mos4.HIV,Clade C and Mosaic gp140 bivalent vaccine"]},{"type":"BIOLOGICAL","name":"Clade C and Mosaic gp140 HIV bivalent vaccine","description":"Participants will receive Clade C and Mosaic gp140 HIV bivalent vaccine as IM injection into the deltoid muscle at Months 6 and 12.","armGroupLabels":["Group1:Ad26.Mos4.HIV,Clade C and Mosaic gp140 bivalent vaccine"]},{"type":"BIOLOGICAL","name":"Placebo","description":"Participants will receive matching placebo.","armGroupLabels":["Group 2: Placebo"]}]},"outcomesModule":{"primaryOutcomes":[{"measure":"Number of Participants With Confirmed Human Immunodeficiency Virus (HIV)-1 Infections Diagnosed Between the Month 7 and Month 24 Visits (Per-protocol [PP] Set)","description":"Number of participants with a confirmed HIV-1 infections diagnosed between the Month 7 and Month 24 visits (PP set) was reported. The data represents the cumulative incidence of HIV-1 infections.","timeFrame":"From Month 7 up to Month 24"},{"measure":"Number of Participants With a Confirmed Human Immunodeficiency Virus (HIV)-1 Infections Diagnosed Between the Month 7 and Month 30 Visits (PP Set)","description":"Number of participants with a confirmed HIV-1 infections diagnosed between the Month 7 and Month 30 visits (PP set) was reported. The data represents the cumulative incidence of HIV-1 infections.","timeFrame":"From Month 7 up to Month 30"}],"secondaryOutcomes":[{"measure":"Number of Participants With Solicited Local Adverse Events (AEs)","description":"Number of participants with solicited local AEs were reported. An AE is any untoward medical occurrence in a participant participating in a clinical study that does not necessarily have a causal relationship with the pharmaceutical/biological agent under study. Solicited local AEs that included injection site pain/tenderness, erythema and swelling at the study vaccine injection site, are used to assess the reactogenicity of the study vaccine and are pre-defined local (injection site) and which were noted by participants in their participant diary for 7 days post vaccination (day of vaccination and the subsequent 7 days).","timeFrame":"Up to 7 days post each vaccination (dose) on Days 1 (up to Day 8), 84 (up to Day 91), 168 (up to Day 175), and 364 (up to 371)"},{"measure":"Number of Participants With Solicited Systemic Adverse Events (AEs)","description":"Number of participants with solicited systemic AEs were reported. An AE is any untoward medical occurrence in a participant participating in a clinical study that does not necessarily have a causal relationship with the pharmaceutical/biological agent under study. Solicited systemic events included events such as fatigue, headache, nausea, and myalgia, for which participants were specifically questioned and which were noted by participants in their participant diary for 7 days post vaccination (day of vaccination and the subsequent 7 days).","timeFrame":"Up to 7 days after each vaccination (dose) on Days 1 (up to Day 8), 84 (up to Day 91), 168 (up to Day 175), and 364 (up to 371)"},{"measure":"Number of Participants With Unsolicited Adverse Events (AEs)","description":"Number of participants with unsolicited AEs were reported. An AE is any untoward medical occurrence in a participant participating in a clinical study that does not necessarily have a causal relationship with the pharmaceutical/biological agent under study. Unsolicited AEs are all AEs for which the participants were not specifically questioned in the participant's diary.","timeFrame":"Up to 28 days after each vaccination (dose) on Days 1 (up to Day 29), 84 (up to Day 112), 168 (up to Day 196), and 364 (up to 392)"},{"measure":"Number of Participants With Adverse Events of Special Interest (AESIs)","description":"Number of participants with AESIs were reported. An AE is any untoward medical occurrence in a participant participating in a clinical study that does not necessarily have a causal relationship with the pharmaceutical/biological agent under study. Thrombotic events and/or thrombocytopenia (defined as platelet count below the lower limit of normal \\[LLN\\] range for the testing lab) were considered to be potential AESIs.","timeFrame":"Up to 6 months after the last vaccination (up to Month 18)"},{"measure":"Number of Participants With Medically-attended Adverse Events (MAAEs)","description":"Number of participants with MAAEs were reported. An AE is any untoward medical occurrence in a participant participating in a clinical study that does not necessarily have a causal relationship with the pharmaceutical/biological agent under study. MAAEs are defined as AEs with medically-attended visits including hospital, emergency room, urgent care clinic, or other visits to or from medical personnel for any reason.","timeFrame":"From Day 1 up to Month 40"},{"measure":"Number of Participants With Serious Adverse Events (SAEs)","description":"Number of participants with SAEs were reported. An AE is any untoward medical occurrence in a participant participating in a clinical study that does not necessarily have a causal relationship with the pharmaceutical/biological agent under study. An SAE is an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly/birth defect; suspected transmission of any infectious agent via a medicinal product or medically important.","timeFrame":"From Day 1 up to Month 40"},{"measure":"Number of Participants Who Discontinued the Study or Study Intervention Due to Adverse Events (AEs)","description":"Number of participants who discontinued the study or study intervention due to AEs were reported. An AE is any untoward medical occurrence in a participant participating in a clinical study that does not necessarily have a causal relationship with the pharmaceutical/biological agent under study.","timeFrame":"From Day 1 up to Month 40"},{"measure":"Number of Participants With a Confirmed Human Immunodeficiency Virus (HIV)-1 Infections Diagnosed Over Time (Modified Intent-to-Treat [mITT] Set)","description":"Number of participants with a confirmed HIV-1 infections diagnosed over time (mITT set) were reported. The data represents the cumulative incidence of HIV-1 infections at specified intervals.","timeFrame":"Month 0 to 24, Month 0 to 30, Month 0 to 40"},{"measure":"Number of Participants With a Confirmed Human Immunodeficiency Virus (HIV)-1 Infections Diagnosed Over Time (Modified Intent-to-Treat-2 [mITT-2] Set)","description":"Number of participants with a confirmed HIV-1 infections diagnosed over time (mITT-2 set) were reported. The data represents the cumulative incidence of HIV-1 infections at specified intervals.","timeFrame":"Month 7 to 24, Month 7 to 30, Month 7 to 40"},{"measure":"Number of Participants With Confirmed Human Immunodeficiency Virus (HIV)-1 Infections Diagnosed Over Time (Modified Intent-to-Treat-3 [mITT-3] Set)","description":"Number of participants with confirmed HIV-1 infection diagnosed over time (mITT-3 set) were reported. The data represents the cumulative incidence of HIV-1 infections at specified intervals.","timeFrame":"Month 7 to 24, Month 7 to 30, Month 7 to 40"},{"measure":"Number of Participants With Confirmed Human Immunodeficiency Virus (HIV)-1 Infections Diagnosed Over Time (Full Immunization Analysis Set [FIS])","description":"Number of participants with confirmed HIV-1 infection diagnosed over time (FIS set) were reported. The data represents the cumulative incidence of HIV-1 infections at specified intervals.","timeFrame":"Month 13 to 24, Month 13 to 30, Month 13 to 40"},{"measure":"Number of Participants With Confirmed Human Immunodeficiency Virus (HIV)-1 Infections as Assessed by Demographic Characteristics: Age Groups","description":"Number of participants with confirmed HIV-1 infection as assessed by demographic characteristics: age groups was reported. Age groups included 18-20, 21-24, 25-29, 30-34, 35-44, and greater than or equal to (\\>=) 45 years. The data represents the cumulative incidence of HIV-1 infections at specified intervals.","timeFrame":"Month 7 to 24, Month 7 to 30, Month 7 to 40"},{"measure":"Number of Participants With Confirmed Human Immunodeficiency Virus (HIV)-1 Infections as Assessed by Demographic Characteristics: Region-Wise Enrollment","description":"Number of participants with confirmed HIV-1 infections as assessed by demographic characteristics: region-wise enrollment was reported. Regions were Latin-America (Argentina, Brazil, Mexico, and Peru), North America (Puerto Rico and United States of America), and Europe (Italy, Poland, and Spain). The data represents the cumulative incidence of HIV-1 infections at specified intervals.","timeFrame":"Month 7 to 24, Month 7 to 30, Month 7 to 40"},{"measure":"Number of Participants With an HIV-1 Infection by Adenovirus Serotype 26 (Ad26) at Baseline","description":"Number of participants with an HIV-1 infection by Ad26 at baseline were reported.","timeFrame":"Baseline (Day 1)"},{"measure":"Geometric Mean Antibody Titers For Adenovirus Serotype 26 (Ad26) as Determined by Vector Neutralization Assay (VNA)","description":"Geometric mean antibody titers for Ad26 as determined by VNA were reported.","timeFrame":"From Day 1 up to Month 40"},{"measure":"Number of Participants With HIV-1 Infection by Pre/Post-exposure Prophylaxis (P[r]EP) Use","description":"Number of participants with HIV-1 infection by P(r)EP use were reported. P(r)EP was assessed with a 4 item survey. Each item was measured on a scale ranging from 1 (strongly disagree) to 5 (strongly agree). Higher scores indicating higher levels of self-efficacy. If participant showed any evidence of P(r)EP use during the period based on questionnaire responses, concomitant medications or dried blood spot analysis, the response was \"yes\". The data represents the cumulative incidence of HIV-1 infections at specified intervals.","timeFrame":"Month 7 to 24, Month 7 to 30, Month 7 to 40"}]},"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Individual is either cis-gender man having sex with cis-gender men and/or transgender individuals or transgender woman having sex with cis-gender men and/or transgender individuals or transgender man having sex with cis-gender men and/or transgender women or gender non-conforming individual having receptive or insertive anal and/or vaginal condom-less intercourse and who is considered by the site staff to be at increased risk for HIV-1 infection. The potential participants must in the last 6 months have had any condom-less receptive anal or vaginal sex (not included is condom-less anal sex within a mutually monogamous relationship \\>=12 months if the partner is HIV negative or living with HIV and virally suppressed) or rectal or urethral gonorrhea or chlamydia or incident syphilis or any stimulant use or any other drug and/or substance which in the local context may be associated with increased HIV transmission (example, cocaine, amphetamine) or 5 or more sex partners\n* Potential participant has a negative test result for HIV-1 and HIV-2 infection less than or equal to (\\<=) 28 days prior to first vaccination\n* Potential participant must be healthy based on medical history, physical examination, and vital sign measurement performed at screening\n* Contraceptive use by participants assigned female at birth and who have not had sexual reassignment surgery should be consistent with local regulations regarding the acceptable methods of contraception for those participating in clinical studies\n* All participants of childbearing potential must have a negative serum beta-human chorionic gonadotropin (beta-hCG) pregnancy test at screening and have a negative urine beta-hCG pregnancy test immediately prior to each study vaccine administration\n\nExclusion Criteria:\n\n* Potential participants choosing to use PrEP. However, once participants are enrolled and received their first vaccination, and they change their mind regarding PrEP usage, they will be allowed to take PrEP according to the site PrEP plan and will continue to receive further vaccinations. The use of long acting PrEP is disallowed from 24 months prior to Day 1\n* Potential participant is a recipient of a HIV-vaccine candidate at any time, or a recipient of other experimental vaccine(s) within the last 12 months prior to Day 1. For participants who received an experimental vaccine (except HIV vaccine) more than 12 months prior to Day 1, documentation of the identity of the experimental vaccine must be provided to the HPX3002/HVTN 706 safety review team, who will determine eligibility on a case by-case basis. Exceptions: participants can be included if the vaccine received (except HIV vaccine) was subsequently licensed or authorized for emergency use (example, Emergency Use Authorization (EUA), Emergency Use Listing (EUL), or similar program). Participants with proof of having received only placebo can also be included. Participants who are currently still in an interventional study of such a licensed/emergency use-authorized vaccine are to be excluded from the current study\n* Potential participant has received an HIV-related mAb, whether licensed or investigational, within the last 12 months prior to Day 1. For participants who received an HIV-related mAb more than 12 months prior to Day 1, documentation of the identity of the mAb must be provided to the HPX3002/HVTN 706 safety review team, who will determine eligibility on a case-by-case basis\n* Potential participant has known allergy or history of anaphylaxis or other serious adverse reactions to vaccines\n* Pregnant, or breast-feeding, or planning to become pregnant while enrolled in this study or within 90 days after the last dose of study vaccination","healthyVolunteers":true,"sex":"ALL","genderBased":true,"genderDescription":"Cis-gender men and transgender individuals who have sex with cis-gender men and/or transgender Individuals.","minimumAge":"18 Years","maximumAge":"60 Years","stdAges":["ADULT"]},"contactsLocationsModule":{"overallOfficials":[{"name":"Janssen Vaccines & Prevention B.V. Clinical Trial","affiliation":"Janssen Vaccines & Prevention B.V.","role":"STUDY_DIRECTOR"}],"locations":[{"facility":"University of Alabama at Birmingham","city":"Birmingham","state":"Alabama","zip":"35222","country":"United States","geoPoint":{"lat":33.52066,"lon":-86.80249}},{"facility":"Bridge HIV","city":"San Francisco","state":"California","zip":"94102","country":"United States","geoPoint":{"lat":37.77493,"lon":-122.41942}},{"facility":"Whitman Walker Health","city":"Washington D.C.","state":"District of Columbia","zip":"20816","country":"United States","geoPoint":{"lat":38.89511,"lon":-77.03637}},{"facility":"University of Miami","city":"Miami","state":"Florida","zip":"33136","country":"United States","geoPoint":{"lat":25.77427,"lon":-80.19366}},{"facility":"Orlando Immunology Center","city":"Orlando","state":"Florida","zip":"32803","country":"United States","geoPoint":{"lat":28.53834,"lon":-81.37924}},{"facility":"Emory University Rollins School of Public Health - Ponce De Leon CRS","city":"Atlanta","state":"Georgia","zip":"30322","country":"United States","geoPoint":{"lat":33.749,"lon":-84.38798}},{"facility":"The Hope Clinic at Emory University","city":"Decatur","state":"Georgia","zip":"30030","country":"United States","geoPoint":{"lat":33.77483,"lon":-84.29631}},{"facility":"University Of Illinois","city":"Chicago","state":"Illinois","zip":"60612","country":"United States","geoPoint":{"lat":41.85003,"lon":-87.65005}},{"facility":"New Orleans Adolescent Trials Unit CRS","city":"New Orleans","state":"Louisiana","zip":"70112","country":"United States","geoPoint":{"lat":29.95465,"lon":-90.07507}},{"facility":"Dana-Farber/Brigham and Women's Hospital","city":"Boston","state":"Massachusetts","zip":"02115","country":"United States","geoPoint":{"lat":42.35843,"lon":-71.05977}},{"facility":"Fenway Health","city":"Boston","state":"Massachusetts","zip":"02215","country":"United States","geoPoint":{"lat":42.35843,"lon":-71.05977}},{"facility":"Rutgers, The State University of New Jersey - The University Hospital/ACTG Network","city":"Newark","state":"New Jersey","zip":"07103","country":"United States","geoPoint":{"lat":40.73566,"lon":-74.17237}},{"facility":"Harlem Prevention Center CRS","city":"New York","state":"New York","zip":"10027","country":"United States","geoPoint":{"lat":40.71427,"lon":-74.00597}},{"facility":"Columbia University Medical Center","city":"New York","state":"New York","zip":"10032","country":"United States","geoPoint":{"lat":40.71427,"lon":-74.00597}},{"facility":"New York Blood Center","city":"New York","state":"New York","zip":"10065","country":"United States","geoPoint":{"lat":40.71427,"lon":-74.00597}},{"facility":"Strong Memorial Infectious Disease","city":"Rochester","state":"New York","zip":"14642","country":"United States","geoPoint":{"lat":43.15478,"lon":-77.61556}},{"facility":"University of Pennsylvania","city":"Philadelphia","state":"Pennsylvania","zip":"19104","country":"United States","geoPoint":{"lat":39.95238,"lon":-75.16362}},{"facility":"Vanderbilt University Medical Center","city":"Nashville","state":"Tennessee","zip":"37212","country":"United States","geoPoint":{"lat":36.16589,"lon":-86.78444}},{"facility":"Gordon E. Crofoot MD","city":"Houston","state":"Texas","zip":"77098","country":"United States","geoPoint":{"lat":29.76328,"lon":-95.36327}},{"facility":"Seattle Vaccine Trials Unit","city":"Seattle","state":"Washington","zip":"98104","country":"United States","geoPoint":{"lat":47.60621,"lon":-122.33207}},{"facility":"Helios Salud Sa","city":"Buenos Aires","zip":"C1141ACG","country":"Argentina","geoPoint":{"lat":-34.61315,"lon":-58.37723}},{"facility":"Fundacion Huesped","city":"Ciudad Autonoma de Buenos Aire","zip":"C1202ABB","country":"Argentina"},{"facility":"Hospital J. M. Ramos Mejía","city":"Ciudad de Buenos Aires","zip":"C1221Adc","country":"Argentina"},{"facility":"Instituto Caici Srl.","city":"Rosario","zip":"S2000PBJ","country":"Argentina","geoPoint":{"lat":-32.94682,"lon":-60.63932}},{"facility":"Universidade Federal De Minas Gerais - Hospital das Clínicas","city":"Belo Horizonte","zip":"30130-100","country":"Brazil","geoPoint":{"lat":-19.92083,"lon":-43.93778}},{"facility":"Centro Medico Sao Francisco","city":"Curitiba","zip":"80810-050","country":"Brazil","geoPoint":{"lat":-25.42778,"lon":-49.27306}},{"facility":"Fundacao de Medicina Tropical Doutor Heitor Vieira Dourado - FMT","city":"Manaus","zip":"69040-000","country":"Brazil","geoPoint":{"lat":-3.10194,"lon":-60.025}},{"facility":"Fundacao Oswaldo Cruz","city":"Rio de Janeiro","zip":"21040-900","country":"Brazil","geoPoint":{"lat":-22.90642,"lon":-43.18223}},{"facility":"Municipio de Nova Iguacu - Hospital Geral de Nova Iguacu","city":"Rio de Janeiro","zip":"26030-380","country":"Brazil","geoPoint":{"lat":-22.90642,"lon":-43.18223}},{"facility":"Instituto de infectologia Emilio Ribas","city":"São Paulo","zip":"01246-900","country":"Brazil","geoPoint":{"lat":-23.5475,"lon":-46.63611}},{"facility":"Hospital Das Clinicas Da Faculdade De Medicina Da USP","city":"São Paulo","zip":"01246-903","country":"Brazil","geoPoint":{"lat":-23.5475,"lon":-46.63611}},{"facility":"Centro de Referencia E Treinamento Dst/Aids","city":"São Paulo","zip":"02141-000","country":"Brazil","geoPoint":{"lat":-23.5475,"lon":-46.63611}},{"facility":"Ospedale San Raffaele","city":"Milan","zip":"20127","country":"Italy","geoPoint":{"lat":42.78235,"lon":12.59836}},{"facility":"Azienda Ospedaliero-Universitaria Policlinico di Modena","city":"Modena","zip":"41124","country":"Italy","geoPoint":{"lat":44.64783,"lon":10.92539}},{"facility":"Istituto nazionale malattie infettive 'L. Spallanzani'","city":"Roma","zip":"00149","country":"Italy","geoPoint":{"lat":44.99364,"lon":11.10642}},{"facility":"Hospital Civil Fray Antonio Alcalde","city":"Guadalajara","zip":"44280","country":"Mexico","geoPoint":{"lat":20.67738,"lon":-103.34749}},{"facility":"Inst. Nal. de Ciencias Med. Y Nutricion Salvador Zubiran","city":"Mexico City","zip":"14000","country":"Mexico","geoPoint":{"lat":19.42847,"lon":-99.12766}},{"facility":"Unidad de Atención Medica e Investigacion en Salud (UNAMIS)","city":"Mérida","zip":"97000","country":"Mexico","geoPoint":{"lat":20.967,"lon":-89.62318}},{"facility":"Centro de Investigaciones Tecnologicas, Biomedica y medio ambientales (CITBM)","city":"Callao","zip":"07066","country":"Peru","geoPoint":{"lat":-12.05162,"lon":-77.13452}},{"facility":"Asociacion Civil Selva Amazonica (ACSA)","city":"Iquitos","zip":"16001","country":"Peru","geoPoint":{"lat":-3.74814,"lon":-73.2529}},{"facility":"Asociacion Civil Via Libre","city":"Lima","zip":"15001","country":"Peru","geoPoint":{"lat":-12.04318,"lon":-77.02824}},{"facility":"Asociacion Civil Impacta Salud y Educacion - Barranco","city":"Lima - Barranco","zip":"Barranco 15063","country":"Peru"},{"facility":"Asociacion Civil Impacta Salud y Educacion- San Miguel CRS","city":"Lima - San Miguel","zip":"15088","country":"Peru"},{"facility":"Neutrum Lekarze M.Hlebowicz i Partnerzy spolka partnerska","city":"Gdansk","zip":"80-462","country":"Poland","geoPoint":{"lat":54.35227,"lon":18.64912}},{"facility":"Wroclawskie Centrum Zdrowia SPZOZ, Poradnia Profilaktyczno-Lecznicza","city":"Wroclaw","zip":"50-136","country":"Poland","geoPoint":{"lat":51.10286,"lon":17.03006}},{"facility":"Clinical Research Puerto Rico Inc","city":"San Juan","zip":"00909","country":"Puerto Rico","geoPoint":{"lat":18.46633,"lon":-66.10572}},{"facility":"University of Puerto Rico","city":"San Juan","zip":"00936-5067","country":"Puerto Rico","geoPoint":{"lat":18.46633,"lon":-66.10572}},{"facility":"Hosp. Univ. Germans Trias I Pujol","city":"Badalona","zip":"08916","country":"Spain","geoPoint":{"lat":41.45004,"lon":2.24741}},{"facility":"Hosp. Univ. Vall D Hebron","city":"Barcelona","zip":"08001","country":"Spain","geoPoint":{"lat":41.38879,"lon":2.15899}},{"facility":"Hosp Reina Sofia","city":"Córdoba","zip":"14004","country":"Spain","geoPoint":{"lat":37.89155,"lon":-4.77275}},{"facility":"Hosp Univ Fund Jimenez Diaz","city":"Madrid","zip":"28015","country":"Spain","geoPoint":{"lat":40.4165,"lon":-3.70256}},{"facility":"Hosp. Clinico San Carlos","city":"Madrid","zip":"28040","country":"Spain","geoPoint":{"lat":40.4165,"lon":-3.70256}},{"facility":"Hosp. Gral. Univ. Valencia","city":"Valencia","zip":"46014","country":"Spain","geoPoint":{"lat":39.47391,"lon":-0.37966}}]},"referencesModule":{"references":[{"pmid":"41314741","type":"DERIVED","citation":"Buchbinder SP, Spinosa Guzman S, Sanchez J, Willems W, Stieh DJ, van Duijn J, van Rosmalen MGM, Hendriks J, Nijs S, Lavreys L, Paez CA, Grinzstejn B, Hutter J, Mann P, Sierra Madero JG, Cahn P, Castagna A, Truyers C, Roels S, Gilbert PB, Carone M, Luedtke A, Corey L, Pau MG, Tomaka F; HVTN 706/HPX3002/Mosaico Study Team. Efficacy and safety of a mosaic HIV-1 vaccine regimen in men who have sex with men and transgender individuals (HVTN 706/HPX3002/Mosaico): a global, randomised, double-blind, placebo-controlled, phase 3 trial. Lancet HIV. 2025 Dec;12(12):e823-e835. doi: 10.1016/S2352-3018(25)00195-X."}]},"ipdSharingStatementModule":{"ipdSharing":"YES","description":"The data sharing policy of the Janssen Pharmaceutical Companies of Johnson \\& Johnson is available at www.janssen.com/clinical-trials/transparency.\n\nAs noted on this site, requests for access to the study data can be submitted through Yale Open Data Access (YODA) Project site at yoda.yale.edu","url":"https://www.janssen.com/clinical-trials/transparency"}},"resultsSection":{"participantFlowModule":{"groups":[{"id":"FG000","title":"Group 1: Ad26.Mos4.HIV + Clade C and Mosaic gp140","description":"Participants received adenovirus serotype 26.Mosaic 4.human immunodeficiency virus (Ad26.Mos4.HIV) 5\\*10\\^10 viral particles (vp) intramuscular (IM) injection into the deltoid muscle as a monotherapy at Months 0 (Day 1) and 3 (Day 84) (preferably the deltoid of the non-dominant upper arm) along with adjuvanted protein formulation consisting of Clade C protein 80 micrograms (mcg), Mosaic protein 75 mcg and adjuvanted aluminum phosphate 425 mcg, into the deltoid muscle at Months 6 (Day 168) and 12 (Day 364) (different deltoid for each injection)."},{"id":"FG001","title":"Group 2: Placebo","description":"Participants received placebo into the deltoid muscle at Months 0 (Day 1), 3 (Day 84; 1 injection), 6 (Day 168) and 12 (Day 364; 2 injections)."}],"periods":[{"title":"Overall Study","milestones":[{"type":"STARTED","achievements":[{"groupId":"FG000","numSubjects":"1948"},{"groupId":"FG001","numSubjects":"1952"}]},{"type":"Treated: Full Analysis Set (FAS)","achievements":[{"groupId":"FG000","numSubjects":"1942"},{"groupId":"FG001","numSubjects":"1945"}]},{"type":"COMPLETED","achievements":[{"groupId":"FG000","numSubjects":"95"},{"groupId":"FG001","numSubjects":"103"}]},{"type":"NOT COMPLETED","achievements":[{"groupId":"FG000","numSubjects":"1853"},{"groupId":"FG001","numSubjects":"1849"}]}],"dropWithdraws":[{"type":"Sponsor's decision","reasons":[{"groupId":"FG000","numSubjects":"1563"},{"groupId":"FG001","numSubjects":"1528"}]},{"type":"Lost to Follow-up","reasons":[{"groupId":"FG000","numSubjects":"139"},{"groupId":"FG001","numSubjects":"146"}]},{"type":"Withdrawal by Subject","reasons":[{"groupId":"FG000","numSubjects":"68"},{"groupId":"FG001","numSubjects":"72"}]},{"type":"Physician Decision","reasons":[{"groupId":"FG000","numSubjects":"34"},{"groupId":"FG001","numSubjects":"48"}]},{"type":"Adverse Event","reasons":[{"groupId":"FG000","numSubjects":"3"},{"groupId":"FG001","numSubjects":"0"}]},{"type":"Death","reasons":[{"groupId":"FG000","numSubjects":"4"},{"groupId":"FG001","numSubjects":"6"}]},{"type":"Protocol Violation","reasons":[{"groupId":"FG000","numSubjects":"1"},{"groupId":"FG001","numSubjects":"4"}]},{"type":"Other","reasons":[{"groupId":"FG000","numSubjects":"35"},{"groupId":"FG001","numSubjects":"38"}]},{"type":"Randomized but not treated","reasons":[{"groupId":"FG000","numSubjects":"6"},{"groupId":"FG001","numSubjects":"7"}]}]}]},"baselineCharacteristicsModule":{"populationDescription":"The full analysis set (FAS) set included all randomized participants who received at least one vaccine administration.","groups":[{"id":"BG000","title":"Group 1: Ad26.Mos4.HIV + Clade C and Mosaic gp140","description":"Participants received adenovirus serotype 26.Mosaic 4.human immunodeficiency virus (Ad26.Mos4.HIV) 5\\*10\\^10 viral particles (vp) intramuscular (IM) injection into the deltoid muscle as a monotherapy at Months 0 (Day 1) and 3 (Day 84) (preferably the deltoid of the non-dominant upper arm) along with adjuvanted protein formulation consisting of Clade C protein 80 micrograms (mcg), Mosaic protein 75 mcg and adjuvanted aluminum phosphate 425 mcg, into the deltoid muscle at Months 6 (Day 168) and 12 (Day 364) (different deltoid for each injection)."},{"id":"BG001","title":"Group 2: Placebo","description":"Participants received placebo into the deltoid muscle at Months 0 (Day 1), 3 (Day 84; 1 injection), 6 (Day 168) and 12 (Day 364; 2 injections)."},{"id":"BG002","title":"Total","description":"Total of all reporting groups"}],"denoms":[{"units":"Participants","counts":[{"groupId":"BG000","value":"1942"},{"groupId":"BG001","value":"1945"},{"groupId":"BG002","value":"3887"}]}],"measures":[{"title":"Age, Continuous","paramType":"MEAN","dispersionType":"STANDARD_DEVIATION","unitOfMeasure":"years","classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"29.7","spread":"8.28"},{"groupId":"BG001","value":"29.9","spread":"8.58"},{"groupId":"BG002","value":"29.8","spread":"8.43"}]}]}]},{"title":"Sex/Gender, Customized","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","classes":[{"categories":[{"title":"Female (at birth)","measurements":[{"groupId":"BG000","value":"9"},{"groupId":"BG001","value":"7"},{"groupId":"BG002","value":"16"}]},{"title":"Male (at birth)","measurements":[{"groupId":"BG000","value":"1933"},{"groupId":"BG001","value":"1937"},{"groupId":"BG002","value":"3870"}]},{"title":"Undifferentiated (at birth)","measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"1"},{"groupId":"BG002","value":"1"}]}]}]},{"title":"Ethnicity (NIH/OMB)","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","classes":[{"categories":[{"title":"Hispanic or Latino","measurements":[{"groupId":"BG000","value":"1690"},{"groupId":"BG001","value":"1675"},{"groupId":"BG002","value":"3365"}]},{"title":"Not Hispanic or Latino","measurements":[{"groupId":"BG000","value":"238"},{"groupId":"BG001","value":"246"},{"groupId":"BG002","value":"484"}]},{"title":"Unknown or Not Reported","measurements":[{"groupId":"BG000","value":"14"},{"groupId":"BG001","value":"24"},{"groupId":"BG002","value":"38"}]}]}]},{"title":"Race (NIH/OMB)","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","classes":[{"categories":[{"title":"American Indian or Alaska Native","measurements":[{"groupId":"BG000","value":"63"},{"groupId":"BG001","value":"59"},{"groupId":"BG002","value":"122"}]},{"title":"Asian","measurements":[{"groupId":"BG000","value":"13"},{"groupId":"BG001","value":"12"},{"groupId":"BG002","value":"25"}]},{"title":"Native Hawaiian or Other Pacific Islander","measurements":[{"groupId":"BG000","value":"3"},{"groupId":"BG001","value":"7"},{"groupId":"BG002","value":"10"}]},{"title":"Black or African American","measurements":[{"groupId":"BG000","value":"140"},{"groupId":"BG001","value":"161"},{"groupId":"BG002","value":"301"}]},{"title":"White","measurements":[{"groupId":"BG000","value":"868"},{"groupId":"BG001","value":"862"},{"groupId":"BG002","value":"1730"}]},{"title":"More than one race","measurements":[{"groupId":"BG000","value":"814"},{"groupId":"BG001","value":"809"},{"groupId":"BG002","value":"1623"}]},{"title":"Unknown or Not Reported","measurements":[{"groupId":"BG000","value":"41"},{"groupId":"BG001","value":"35"},{"groupId":"BG002","value":"76"}]}]}]},{"title":"Region of Enrollment","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","classes":[{"title":"Argentina","categories":[{"measurements":[{"groupId":"BG000","value":"202"},{"groupId":"BG001","value":"203"},{"groupId":"BG002","value":"405"}]}]},{"title":"Brazil","categories":[{"measurements":[{"groupId":"BG000","value":"425"},{"groupId":"BG001","value":"426"},{"groupId":"BG002","value":"851"}]}]},{"title":"Italy","categories":[{"measurements":[{"groupId":"BG000","value":"46"},{"groupId":"BG001","value":"44"},{"groupId":"BG002","value":"90"}]}]},{"title":"Mexico","categories":[{"measurements":[{"groupId":"BG000","value":"175"},{"groupId":"BG001","value":"172"},{"groupId":"BG002","value":"347"}]}]},{"title":"Peru","categories":[{"measurements":[{"groupId":"BG000","value":"812"},{"groupId":"BG001","value":"808"},{"groupId":"BG002","value":"1620"}]}]},{"title":"Poland","categories":[{"measurements":[{"groupId":"BG000","value":"57"},{"groupId":"BG001","value":"60"},{"groupId":"BG002","value":"117"}]}]},{"title":"Puerto Rico","categories":[{"measurements":[{"groupId":"BG000","value":"5"},{"groupId":"BG001","value":"5"},{"groupId":"BG002","value":"10"}]}]},{"title":"Spain","categories":[{"measurements":[{"groupId":"BG000","value":"128"},{"groupId":"BG001","value":"130"},{"groupId":"BG002","value":"258"}]}]},{"title":"United States","categories":[{"measurements":[{"groupId":"BG000","value":"92"},{"groupId":"BG001","value":"97"},{"groupId":"BG002","value":"189"}]}]}]}]},"outcomeMeasuresModule":{"outcomeMeasures":[{"type":"PRIMARY","title":"Number of Participants With Confirmed Human Immunodeficiency Virus (HIV)-1 Infections Diagnosed Between the Month 7 and Month 24 Visits (Per-protocol [PP] Set)","description":"Number of participants with a confirmed HIV-1 infections diagnosed between the Month 7 and Month 24 visits (PP set) was reported. The data represents the cumulative incidence of HIV-1 infections.","populationDescription":"The PP set included all participants in the full analysis set (FAS; all randomized participants who received at least one vaccine administration) population who had a negative HIV test 4 weeks post 3rd vaccination visit (that is, at the Month 7 Visit) and who received all planned vaccinations at the first three vaccination visits within the respective visit windows.","reportingStatus":"POSTED","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","timeFrame":"From Month 7 up to Month 24","groups":[{"id":"OG000","title":"Group 1: Ad26.Mos4.HIV + Clade C and Mosaic gp140","description":"Participants received adenovirus serotype 26.Mosaic 4.human immunodeficiency virus (Ad26.Mos4.HIV) 5\\*10\\^10 viral particles (vp) intramuscular (IM) injection into the deltoid muscle as a monotherapy at Months 0 (Day 1) and 3 (Day 84) (preferably the deltoid of the non-dominant upper arm) along with adjuvanted protein formulation consisting of Clade C protein 80 micrograms (mcg), Mosaic protein 75 mcg and adjuvanted aluminum phosphate 425 mcg, into the deltoid muscle at Months 6 (Day 168) and 12 (Day 364) (different deltoid for each injection)."},{"id":"OG001","title":"Group 2: Placebo","description":"Participants received placebo into the deltoid muscle at Months 0 (Day 1), 3 (Day 84; 1 injection), 6 (Day 168) and 12 (Day 364; 2 injections)."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"1525"},{"groupId":"OG001","value":"1494"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"65"},{"groupId":"OG001","value":"58"}]}]}]},{"type":"PRIMARY","title":"Number of Participants With a Confirmed Human Immunodeficiency Virus (HIV)-1 Infections Diagnosed Between the Month 7 and Month 30 Visits (PP Set)","description":"Number of participants with a confirmed HIV-1 infections diagnosed between the Month 7 and Month 30 visits (PP set) was reported. The data represents the cumulative incidence of HIV-1 infections.","populationDescription":"The PP set included all participants in the FAS (all randomized participants who received at least one vaccine administration) population who had a negative HIV test 4 weeks post 3rd vaccination visit (that is, at the Month 7 Visit) and who received all planned vaccinations at the first three vaccination visits within the respective visit windows.","reportingStatus":"POSTED","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","timeFrame":"From Month 7 up to Month 30","groups":[{"id":"OG000","title":"Group 1: Ad26.Mos4.HIV + Clade C and Mosaic gp140","description":"Participants received adenovirus serotype 26.Mosaic 4.human immunodeficiency virus (Ad26.Mos4.HIV) 5\\*10\\^10 viral particles (vp) intramuscular (IM) injection into the deltoid muscle as a monotherapy at Months 0 (Day 1) and 3 (Day 84) (preferably the deltoid of the non-dominant upper arm) along with adjuvanted protein formulation consisting of Clade C protein 80 micrograms (mcg), Mosaic protein 75 mcg and adjuvanted aluminum phosphate 425 mcg, into the deltoid muscle at Months 6 (Day 168) and 12 (Day 364) (different deltoid for each injection)."},{"id":"OG001","title":"Group 2: Placebo","description":"Participants received placebo into the deltoid muscle at Months 0 (Day 1), 3 (Day 84; 1 injection), 6 (Day 168) and 12 (Day 364; 2 injections)."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"1525"},{"groupId":"OG001","value":"1494"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"71"},{"groupId":"OG001","value":"67"}]}]}]},{"type":"SECONDARY","title":"Number of Participants With Solicited Local Adverse Events (AEs)","description":"Number of participants with solicited local AEs were reported. An AE is any untoward medical occurrence in a participant participating in a clinical study that does not necessarily have a causal relationship with the pharmaceutical/biological agent under study. Solicited local AEs that included injection site pain/tenderness, erythema and swelling at the study vaccine injection site, are used to assess the reactogenicity of the study vaccine and are pre-defined local (injection site) and which were noted by participants in their participant diary for 7 days post vaccination (day of vaccination and the subsequent 7 days).","populationDescription":"The FAS set included all randomized participants who received at least one vaccine administration. Here, 'n' (number analyzed) is defined as participants analyzed at specified timepoints.","reportingStatus":"POSTED","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","timeFrame":"Up to 7 days post each vaccination (dose) on Days 1 (up to Day 8), 84 (up to Day 91), 168 (up to Day 175), and 364 (up to 371)","groups":[{"id":"OG000","title":"Group 1: Ad26.Mos4.HIV + Clade C and Mosaic gp140","description":"Participants received adenovirus serotype 26.Mosaic 4.human immunodeficiency virus (Ad26.Mos4.HIV) 5\\*10\\^10 viral particles (vp) intramuscular (IM) injection into the deltoid muscle as a monotherapy at Months 0 (Day 1) and 3 (Day 84) (preferably the deltoid of the non-dominant upper arm) along with adjuvanted protein formulation consisting of Clade C protein 80 micrograms (mcg), Mosaic protein 75 mcg and adjuvanted aluminum phosphate 425 mcg, into the deltoid muscle at Months 6 (Day 168) and 12 (Day 364) (different deltoid for each injection)."},{"id":"OG001","title":"Group 2: Placebo","description":"Participants received placebo into the deltoid muscle at Months 0 (Day 1), 3 (Day 84; 1 injection), 6 (Day 168) and 12 (Day 364; 2 injections)."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"1942"},{"groupId":"OG001","value":"1945"}]}],"classes":[{"title":"Up to 7 days post dose on Day 1","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"1942"},{"groupId":"OG001","value":"1945"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"1225"},{"groupId":"OG001","value":"329"}]}]},{"title":"Up to 7 days post dose on Day 84","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"1888"},{"groupId":"OG001","value":"1877"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"905"},{"groupId":"OG001","value":"239"}]}]},{"title":"Up to 7 days post dose on Day 168","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"1841"},{"groupId":"OG001","value":"1816"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"1010"},{"groupId":"OG001","value":"319"}]}]},{"title":"Up to 7 days post dose on Day 364","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"1724"},{"groupId":"OG001","value":"1715"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"917"},{"groupId":"OG001","value":"252"}]}]}]},{"type":"SECONDARY","title":"Number of Participants With Solicited Systemic Adverse Events (AEs)","description":"Number of participants with solicited systemic AEs were reported. An AE is any untoward medical occurrence in a participant participating in a clinical study that does not necessarily have a causal relationship with the pharmaceutical/biological agent under study. Solicited systemic events included events such as fatigue, headache, nausea, and myalgia, for which participants were specifically questioned and which were noted by participants in their participant diary for 7 days post vaccination (day of vaccination and the subsequent 7 days).","populationDescription":"The FAS set included all randomized participants who received at least one vaccine administration. Here, 'n' (number analyzed) is defined as participants analyzed at specified timepoints.","reportingStatus":"POSTED","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","timeFrame":"Up to 7 days after each vaccination (dose) on Days 1 (up to Day 8), 84 (up to Day 91), 168 (up to Day 175), and 364 (up to 371)","groups":[{"id":"OG000","title":"Group 1: Ad26.Mos4.HIV + Clade C and Mosaic gp140","description":"Participants received adenovirus serotype 26.Mosaic 4.human immunodeficiency virus (Ad26.Mos4.HIV) 5\\*10\\^10 viral particles (vp) intramuscular (IM) injection into the deltoid muscle as a monotherapy at Months 0 (Day 1) and 3 (Day 84) (preferably the deltoid of the non-dominant upper arm) along with adjuvanted protein formulation consisting of Clade C protein 80 micrograms (mcg), Mosaic protein 75 mcg and adjuvanted aluminum phosphate 425 mcg, into the deltoid muscle at Months 6 (Day 168) and 12 (Day 364) (different deltoid for each injection)."},{"id":"OG001","title":"Group 2: Placebo","description":"Participants received placebo into the deltoid muscle at Months 0 (Day 1), 3 (Day 84; 1 injection), 6 (Day 168) and 12 (Day 364; 2 injections)."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"1942"},{"groupId":"OG001","value":"1945"}]}],"classes":[{"title":"Up to 7 days post dose on Day 1","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"1942"},{"groupId":"OG001","value":"1945"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"1313"},{"groupId":"OG001","value":"860"}]}]},{"title":"Up to 7 days post dose on Day 84","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"1888"},{"groupId":"OG001","value":"1877"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"891"},{"groupId":"OG001","value":"572"}]}]},{"title":"Up to 7 days post dose on Day 168","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"1841"},{"groupId":"OG001","value":"1816"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"856"},{"groupId":"OG001","value":"535"}]}]},{"title":"Up to 7 days post dose on Day 371","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"1724"},{"groupId":"OG001","value":"1715"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"759"},{"groupId":"OG001","value":"432"}]}]}]},{"type":"SECONDARY","title":"Number of Participants With Unsolicited Adverse Events (AEs)","description":"Number of participants with unsolicited AEs were reported. An AE is any untoward medical occurrence in a participant participating in a clinical study that does not necessarily have a causal relationship with the pharmaceutical/biological agent under study. Unsolicited AEs are all AEs for which the participants were not specifically questioned in the participant's diary.","populationDescription":"The FAS set included all randomized participants who received at least one vaccine administration. Here, 'n' (number analyzed) is defined as participants analyzed at specified timepoints.","reportingStatus":"POSTED","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","timeFrame":"Up to 28 days after each vaccination (dose) on Days 1 (up to Day 29), 84 (up to Day 112), 168 (up to Day 196), and 364 (up to 392)","groups":[{"id":"OG000","title":"Group 1: Ad26.Mos4.HIV + Clade C and Mosaic gp140","description":"Participants received adenovirus serotype 26.Mosaic 4.human immunodeficiency virus (Ad26.Mos4.HIV) 5\\*10\\^10 viral particles (vp) intramuscular (IM) injection into the deltoid muscle as a monotherapy at Months 0 (Day 1) and 3 (Day 84) (preferably the deltoid of the non-dominant upper arm) along with adjuvanted protein formulation consisting of Clade C protein 80 micrograms (mcg), Mosaic protein 75 mcg and adjuvanted aluminum phosphate 425 mcg, into the deltoid muscle at Months 6 (Day 168) and 12 (Day 364) (different deltoid for each injection)."},{"id":"OG001","title":"Group 2: Placebo","description":"Participants received placebo into the deltoid muscle at Months 0 (Day 1), 3 (Day 84; 1 injection), 6 (Day 168) and 12 (Day 364; 2 injections)."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"1942"},{"groupId":"OG001","value":"1945"}]}],"classes":[{"title":"Up to 28 days post dose on Day 1","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"1942"},{"groupId":"OG001","value":"1945"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"253"},{"groupId":"OG001","value":"245"}]}]},{"title":"Up to 28 days post dose on Day 84","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"1888"},{"groupId":"OG001","value":"1877"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"190"},{"groupId":"OG001","value":"191"}]}]},{"title":"Up to 28 days post dose on Day 168","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"1841"},{"groupId":"OG001","value":"1816"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"298"},{"groupId":"OG001","value":"293"}]}]},{"title":"Up to 28 days post dose on Day 364","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"1724"},{"groupId":"OG001","value":"1715"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"249"},{"groupId":"OG001","value":"297"}]}]}]},{"type":"SECONDARY","title":"Number of Participants With Adverse Events of Special Interest (AESIs)","description":"Number of participants with AESIs were reported. An AE is any untoward medical occurrence in a participant participating in a clinical study that does not necessarily have a causal relationship with the pharmaceutical/biological agent under study. Thrombotic events and/or thrombocytopenia (defined as platelet count below the lower limit of normal \\[LLN\\] range for the testing lab) were considered to be potential AESIs.","populationDescription":"The FAS set included all randomized participants who received at least one vaccine administration.","reportingStatus":"POSTED","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","timeFrame":"Up to 6 months after the last vaccination (up to Month 18)","groups":[{"id":"OG000","title":"Group 1: Ad26.Mos4.HIV + Clade C and Mosaic gp140","description":"Participants received adenovirus serotype 26.Mosaic 4.human immunodeficiency virus (Ad26.Mos4.HIV) 5\\*10\\^10 viral particles (vp) intramuscular (IM) injection into the deltoid muscle as a monotherapy at Months 0 (Day 1) and 3 (Day 84) (preferably the deltoid of the non-dominant upper arm) along with adjuvanted protein formulation consisting of Clade C protein 80 micrograms (mcg), Mosaic protein 75 mcg and adjuvanted aluminum phosphate 425 mcg, into the deltoid muscle at Months 6 (Day 168) and 12 (Day 364) (different deltoid for each injection)."},{"id":"OG001","title":"Group 2: Placebo","description":"Participants received placebo into the deltoid muscle at Months 0 (Day 1), 3 (Day 84; 1 injection), 6 (Day 168) and 12 (Day 364; 2 injections)."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"1942"},{"groupId":"OG001","value":"1945"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"4"},{"groupId":"OG001","value":"2"}]}]}]},{"type":"SECONDARY","title":"Number of Participants With Medically-attended Adverse Events (MAAEs)","description":"Number of participants with MAAEs were reported. An AE is any untoward medical occurrence in a participant participating in a clinical study that does not necessarily have a causal relationship with the pharmaceutical/biological agent under study. MAAEs are defined as AEs with medically-attended visits including hospital, emergency room, urgent care clinic, or other visits to or from medical personnel for any reason.","populationDescription":"The FAS set included all randomized participants who received at least one vaccine administration.","reportingStatus":"POSTED","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","timeFrame":"From Day 1 up to Month 40","groups":[{"id":"OG000","title":"Group 1: Ad26.Mos4.HIV + Clade C and Mosaic gp140","description":"Participants received adenovirus serotype 26.Mosaic 4.human immunodeficiency virus (Ad26.Mos4.HIV) 5\\*10\\^10 viral particles (vp) intramuscular (IM) injection into the deltoid muscle as a monotherapy at Months 0 (Day 1) and 3 (Day 84) (preferably the deltoid of the non-dominant upper arm) along with adjuvanted protein formulation consisting of Clade C protein 80 micrograms (mcg), Mosaic protein 75 mcg and adjuvanted aluminum phosphate 425 mcg, into the deltoid muscle at Months 6 (Day 168) and 12 (Day 364) (different deltoid for each injection)."},{"id":"OG001","title":"Group 2: Placebo","description":"Participants received placebo into the deltoid muscle at Months 0 (Day 1), 3 (Day 84; 1 injection), 6 (Day 168) and 12 (Day 364; 2 injections)."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"1942"},{"groupId":"OG001","value":"1945"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"999"},{"groupId":"OG001","value":"1002"}]}]}]},{"type":"SECONDARY","title":"Number of Participants With Serious Adverse Events (SAEs)","description":"Number of participants with SAEs were reported. An AE is any untoward medical occurrence in a participant participating in a clinical study that does not necessarily have a causal relationship with the pharmaceutical/biological agent under study. An SAE is an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly/birth defect; suspected transmission of any infectious agent via a medicinal product or medically important.","populationDescription":"The FAS set included all randomized participants who received at least one vaccine administration.","reportingStatus":"POSTED","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","timeFrame":"From Day 1 up to Month 40","groups":[{"id":"OG000","title":"Group 1: Ad26.Mos4.HIV + Clade C and Mosaic gp140","description":"Participants received adenovirus serotype 26.Mosaic 4.human immunodeficiency virus (Ad26.Mos4.HIV) 5\\*10\\^10 viral particles (vp) intramuscular (IM) injection into the deltoid muscle as a monotherapy at Months 0 (Day 1) and 3 (Day 84) (preferably the deltoid of the non-dominant upper arm) along with adjuvanted protein formulation consisting of Clade C protein 80 micrograms (mcg), Mosaic protein 75 mcg and adjuvanted aluminum phosphate 425 mcg, into the deltoid muscle at Months 6 (Day 168) and 12 (Day 364) (different deltoid for each injection)."},{"id":"OG001","title":"Group 2: Placebo","description":"Participants received placebo into the deltoid muscle at Months 0 (Day 1), 3 (Day 84; 1 injection), 6 (Day 168) and 12 (Day 364; 2 injections)."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"1942"},{"groupId":"OG001","value":"1945"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"82"},{"groupId":"OG001","value":"77"}]}]}]},{"type":"SECONDARY","title":"Number of Participants Who Discontinued the Study or Study Intervention Due to Adverse Events (AEs)","description":"Number of participants who discontinued the study or study intervention due to AEs were reported. An AE is any untoward medical occurrence in a participant participating in a clinical study that does not necessarily have a causal relationship with the pharmaceutical/biological agent under study.","populationDescription":"The FAS set included all randomized participants who received at least one vaccine administration.","reportingStatus":"POSTED","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","timeFrame":"From Day 1 up to Month 40","groups":[{"id":"OG000","title":"Group 1: Ad26.Mos4.HIV + Clade C and Mosaic gp140","description":"Participants received adenovirus serotype 26.Mosaic 4.human immunodeficiency virus (Ad26.Mos4.HIV) 5\\*10\\^10 viral particles (vp) intramuscular (IM) injection into the deltoid muscle as a monotherapy at Months 0 (Day 1) and 3 (Day 84) (preferably the deltoid of the non-dominant upper arm) along with adjuvanted protein formulation consisting of Clade C protein 80 micrograms (mcg), Mosaic protein 75 mcg and adjuvanted aluminum phosphate 425 mcg, into the deltoid muscle at Months 6 (Day 168) and 12 (Day 364) (different deltoid for each injection)."},{"id":"OG001","title":"Group 2: Placebo","description":"Participants received placebo into the deltoid muscle at Months 0 (Day 1), 3 (Day 84; 1 injection), 6 (Day 168) and 12 (Day 364; 2 injections)."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"1942"},{"groupId":"OG001","value":"1945"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"11"},{"groupId":"OG001","value":"16"}]}]}]},{"type":"SECONDARY","title":"Number of Participants With a Confirmed Human Immunodeficiency Virus (HIV)-1 Infections Diagnosed Over Time (Modified Intent-to-Treat [mITT] Set)","description":"Number of participants with a confirmed HIV-1 infections diagnosed over time (mITT set) were reported. The data represents the cumulative incidence of HIV-1 infections at specified intervals.","populationDescription":"The mITT efficacy population included participants in the FAS who were HIV-1 uninfected at the date of the first vaccination.","reportingStatus":"POSTED","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","timeFrame":"Month 0 to 24, Month 0 to 30, Month 0 to 40","groups":[{"id":"OG000","title":"Group 1: Ad26.Mos4.HIV + Clade C and Mosaic gp140","description":"Participants received adenovirus serotype 26.Mosaic 4.human immunodeficiency virus (Ad26.Mos4.HIV) 5\\*10\\^10 viral particles (vp) intramuscular (IM) injection into the deltoid muscle as a monotherapy at Months 0 (Day 1) and 3 (Day 84) (preferably the deltoid of the non-dominant upper arm) along with adjuvanted protein formulation consisting of Clade C protein 80 micrograms (mcg), Mosaic protein 75 mcg and adjuvanted aluminum phosphate 425 mcg, into the deltoid muscle at Months 6 (Day 168) and 12 (Day 364) (different deltoid for each injection)."},{"id":"OG001","title":"Group 2: Placebo","description":"Participants received placebo into the deltoid muscle at Months 0 (Day 1), 3 (Day 84; 1 injection), 6 (Day 168) and 12 (Day 364; 2 injections)."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"1940"},{"groupId":"OG001","value":"1938"}]}],"classes":[{"title":"Month 0 to 24","categories":[{"measurements":[{"groupId":"OG000","value":"124"},{"groupId":"OG001","value":"123"}]}]},{"title":"Month 0 to 30","categories":[{"measurements":[{"groupId":"OG000","value":"130"},{"groupId":"OG001","value":"132"}]}]},{"title":"Month 0 to 40","categories":[{"measurements":[{"groupId":"OG000","value":"130"},{"groupId":"OG001","value":"133"}]}]}]},{"type":"SECONDARY","title":"Number of Participants With a Confirmed Human Immunodeficiency Virus (HIV)-1 Infections Diagnosed Over Time (Modified Intent-to-Treat-2 [mITT-2] Set)","description":"Number of participants with a confirmed HIV-1 infections diagnosed over time (mITT-2 set) were reported. The data represents the cumulative incidence of HIV-1 infections at specified intervals.","populationDescription":"The mITT-2 efficacy population included participants in the FAS who had a negative HIV test 4 weeks post third vaccination visit (that is, at the Month 7 Visit).","reportingStatus":"POSTED","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","timeFrame":"Month 7 to 24, Month 7 to 30, Month 7 to 40","groups":[{"id":"OG000","title":"Group 1: Ad26.Mos4.HIV + Clade C and Mosaic gp140","description":"Participants received adenovirus serotype 26.Mosaic 4.human immunodeficiency virus (Ad26.Mos4.HIV) 5\\*10\\^10 viral particles (vp) intramuscular (IM) injection into the deltoid muscle as a monotherapy at Months 0 (Day 1) and 3 (Day 84) (preferably the deltoid of the non-dominant upper arm) along with adjuvanted protein formulation consisting of Clade C protein 80 micrograms (mcg), Mosaic protein 75 mcg and adjuvanted aluminum phosphate 425 mcg, into the deltoid muscle at Months 6 (Day 168) and 12 (Day 364) (different deltoid for each injection)."},{"id":"OG001","title":"Group 2: Placebo","description":"Participants received placebo into the deltoid muscle at Months 0 (Day 1), 3 (Day 84; 1 injection), 6 (Day 168) and 12 (Day 364; 2 injections)."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"1812"},{"groupId":"OG001","value":"1796"}]}],"classes":[{"title":"Month 7 to 24","categories":[{"measurements":[{"groupId":"OG000","value":"75"},{"groupId":"OG001","value":"71"}]}]},{"title":"Month 7 to 30","categories":[{"measurements":[{"groupId":"OG000","value":"81"},{"groupId":"OG001","value":"80"}]}]},{"title":"Month 7 to 40","categories":[{"measurements":[{"groupId":"OG000","value":"81"},{"groupId":"OG001","value":"81"}]}]}]},{"type":"SECONDARY","title":"Number of Participants With Confirmed Human Immunodeficiency Virus (HIV)-1 Infections Diagnosed Over Time (Modified Intent-to-Treat-3 [mITT-3] Set)","description":"Number of participants with confirmed HIV-1 infection diagnosed over time (mITT-3 set) were reported. The data represents the cumulative incidence of HIV-1 infections at specified intervals.","populationDescription":"The mITT-3 efficacy population included participants in the FAS who had a negative HIV test 4 weeks post third vaccination visit (that is, at the Month 7 Visit) and who received all planned vaccinations at the first three vaccination visits regardless of the fact if the vaccinations were within the visit windows.","reportingStatus":"POSTED","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","timeFrame":"Month 7 to 24, Month 7 to 30, Month 7 to 40","groups":[{"id":"OG000","title":"Group 1: Ad26.Mos4.HIV + Clade C and Mosaic gp140","description":"Participants received adenovirus serotype 26.Mosaic 4.human immunodeficiency virus (Ad26.Mos4.HIV) 5\\*10\\^10 viral particles (vp) intramuscular (IM) injection into the deltoid muscle as a monotherapy at Months 0 (Day 1) and 3 (Day 84) (preferably the deltoid of the non-dominant upper arm) along with adjuvanted protein formulation consisting of Clade C protein 80 micrograms (mcg), Mosaic protein 75 mcg and adjuvanted aluminum phosphate 425 mcg, into the deltoid muscle at Months 6 (Day 168) and 12 (Day 364) (different deltoid for each injection)."},{"id":"OG001","title":"Group 2: Placebo","description":"Participants received placebo into the deltoid muscle at Months 0 (Day 1), 3 (Day 84; 1 injection), 6 (Day 168) and 12 (Day 364; 2 injections)."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"1793"},{"groupId":"OG001","value":"1775"}]}],"classes":[{"title":"Month 7 to 24","categories":[{"measurements":[{"groupId":"OG000","value":"75"},{"groupId":"OG001","value":"71"}]}]},{"title":"Month 7 to 30","categories":[{"measurements":[{"groupId":"OG000","value":"81"},{"groupId":"OG001","value":"80"}]}]},{"title":"Month 7 to 40","categories":[{"measurements":[{"groupId":"OG000","value":"81"},{"groupId":"OG001","value":"81"}]}]}]},{"type":"SECONDARY","title":"Number of Participants With Confirmed Human Immunodeficiency Virus (HIV)-1 Infections Diagnosed Over Time (Full Immunization Analysis Set [FIS])","description":"Number of participants with confirmed HIV-1 infection diagnosed over time (FIS set) were reported. The data represents the cumulative incidence of HIV-1 infections at specified intervals.","populationDescription":"The FIS included participants in the FAS who were HIV-1 uninfected 4 weeks after the fourth vaccination visit (that is, at Month 13 Visit) and who received all planned vaccinations within the respective visit windows.","reportingStatus":"POSTED","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","timeFrame":"Month 13 to 24, Month 13 to 30, Month 13 to 40","groups":[{"id":"OG000","title":"Group 1: Ad26.Mos4.HIV + Clade C and Mosaic gp140","description":"Participants received adenovirus serotype 26.Mosaic 4.human immunodeficiency virus (Ad26.Mos4.HIV) 5\\*10\\^10 viral particles (vp) intramuscular (IM) injection into the deltoid muscle as a monotherapy at Months 0 (Day 1) and 3 (Day 84) (preferably the deltoid of the non-dominant upper arm) along with adjuvanted protein formulation consisting of Clade C protein 80 micrograms (mcg), Mosaic protein 75 mcg and adjuvanted aluminum phosphate 425 mcg, into the deltoid muscle at Months 6 (Day 168) and 12 (Day 364) (different deltoid for each injection)."},{"id":"OG001","title":"Group 2: Placebo","description":"Participants received placebo into the deltoid muscle at Months 0 (Day 1), 3 (Day 84; 1 injection), 6 (Day 168) and 12 (Day 364; 2 injections)."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"1383"},{"groupId":"OG001","value":"1376"}]}],"classes":[{"title":"Month 13 to 24","categories":[{"measurements":[{"groupId":"OG000","value":"22"},{"groupId":"OG001","value":"22"}]}]},{"title":"Month 13 to 30","categories":[{"measurements":[{"groupId":"OG000","value":"28"},{"groupId":"OG001","value":"31"}]}]},{"title":"Month 13 to 40","categories":[{"measurements":[{"groupId":"OG000","value":"28"},{"groupId":"OG001","value":"32"}]}]}]},{"type":"SECONDARY","title":"Number of Participants With Confirmed Human Immunodeficiency Virus (HIV)-1 Infections as Assessed by Demographic Characteristics: Age Groups","description":"Number of participants with confirmed HIV-1 infection as assessed by demographic characteristics: age groups was reported. Age groups included 18-20, 21-24, 25-29, 30-34, 35-44, and greater than or equal to (\\>=) 45 years. The data represents the cumulative incidence of HIV-1 infections at specified intervals.","populationDescription":"The PP set included all participants in the FAS (who received at least one vaccine administration) population who had a negative HIV test 4 weeks post third vaccination visit (that is, at Month 7 Visit) and who received all planned vaccinations at the first 3 vaccination visits within the respective visit windows. Here, 'n' (number analyzed) indicated participants analyzed at specified timepoints.","reportingStatus":"POSTED","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","timeFrame":"Month 7 to 24, Month 7 to 30, Month 7 to 40","groups":[{"id":"OG000","title":"Group 1: Ad26.Mos4.HIV + Clade C and Mosaic gp140","description":"Participants received adenovirus serotype 26.Mosaic 4.human immunodeficiency virus (Ad26.Mos4.HIV) 5\\*10\\^10 viral particles (vp) intramuscular (IM) injection into the deltoid muscle as a monotherapy at Months 0 (Day 1) and 3 (Day 84) (preferably the deltoid of the non-dominant upper arm) along with adjuvanted protein formulation consisting of Clade C protein 80 micrograms (mcg), Mosaic protein 75 mcg and adjuvanted aluminum phosphate 425 mcg, into the deltoid muscle at Months 6 (Day 168) and 12 (Day 364) (different deltoid for each injection)."},{"id":"OG001","title":"Group 2: Placebo","description":"Participants received placebo into the deltoid muscle at Months 0 (Day 1), 3 (Day 84; 1 injection), 6 (Day 168) and 12 (Day 364; 2 injections)."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"1525"},{"groupId":"OG001","value":"1494"}]}],"classes":[{"title":"Month 7 to 24 (Age Group: 18-20 years)","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"140"},{"groupId":"OG001","value":"138"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"8"},{"groupId":"OG001","value":"7"}]}]},{"title":"Month 7 to 24 (Age Group: 21-24 years)","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"298"},{"groupId":"OG001","value":"275"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"15"},{"groupId":"OG001","value":"17"}]}]},{"title":"Month 7 to 24 (Age Group: 25-29 years)","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"406"},{"groupId":"OG001","value":"414"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"21"},{"groupId":"OG001","value":"17"}]}]},{"title":"Month 7 to 24 (Age Group: 30-34 years)","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"296"},{"groupId":"OG001","value":"288"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"7"},{"groupId":"OG001","value":"7"}]}]},{"title":"Month 7 to 24 (Age Group: 35-44 years)","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"274"},{"groupId":"OG001","value":"256"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"12"},{"groupId":"OG001","value":"6"}]}]},{"title":"Month 7 to 24 (Age Group: >=45 years)","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"111"},{"groupId":"OG001","value":"123"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"2"},{"groupId":"OG001","value":"4"}]}]},{"title":"Month 7 to 30 (Age Group: 18-20 years)","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"140"},{"groupId":"OG001","value":"138"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"9"},{"groupId":"OG001","value":"10"}]}]},{"title":"Month 7 to 30 (Age Group: 21-24 years)","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"298"},{"groupId":"OG001","value":"275"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"18"},{"groupId":"OG001","value":"17"}]}]},{"title":"Month 7 to 30 (Age Group: 25-29 years)","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"406"},{"groupId":"OG001","value":"414"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"22"},{"groupId":"OG001","value":"21"}]}]},{"title":"Month 7 to 30 (Age Group: 30-34 years)","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"296"},{"groupId":"OG001","value":"288"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"8"},{"groupId":"OG001","value":"8"}]}]},{"title":"Month 7 to 30 (Age Group: 35-44 years)","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"274"},{"groupId":"OG001","value":"256"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"12"},{"groupId":"OG001","value":"7"}]}]},{"title":"Month 7 to 30 (Age Group: >=45 years)","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"111"},{"groupId":"OG001","value":"123"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"2"},{"groupId":"OG001","value":"4"}]}]},{"title":"Month 7 to 40 (Age Group: 18-20 years)","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"140"},{"groupId":"OG001","value":"138"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"9"},{"groupId":"OG001","value":"10"}]}]},{"title":"Month 7 to 40 (Age Group: 21-24 years)","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"298"},{"groupId":"OG001","value":"275"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"18"},{"groupId":"OG001","value":"17"}]}]},{"title":"Month 7 to 40 (Age Group: 25-29 years)","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"406"},{"groupId":"OG001","value":"414"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"22"},{"groupId":"OG001","value":"22"}]}]},{"title":"Month 7 to 40 (Age Group: 30-34 years)","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"296"},{"groupId":"OG001","value":"288"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"8"},{"groupId":"OG001","value":"8"}]}]},{"title":"Month 7 to 40 (Age Group: 35-44 years)","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"274"},{"groupId":"OG001","value":"256"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"12"},{"groupId":"OG001","value":"7"}]}]},{"title":"Month 7 to 40 (Age Group: >=45 years)","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"111"},{"groupId":"OG001","value":"123"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"2"},{"groupId":"OG001","value":"4"}]}]}]},{"type":"SECONDARY","title":"Number of Participants With Confirmed Human Immunodeficiency Virus (HIV)-1 Infections as Assessed by Demographic Characteristics: Region-Wise Enrollment","description":"Number of participants with confirmed HIV-1 infections as assessed by demographic characteristics: region-wise enrollment was reported. Regions were Latin-America (Argentina, Brazil, Mexico, and Peru), North America (Puerto Rico and United States of America), and Europe (Italy, Poland, and Spain). The data represents the cumulative incidence of HIV-1 infections at specified intervals.","populationDescription":"The PP set included all participants in the FAS (who received at least one vaccine administration) population who had a negative HIV test 4 weeks post third vaccination visit (that is, at Month 7 Visit) and who received all planned vaccinations at the first 3 vaccination visits within the respective visit windows. Here, 'n' (number analyzed) indicated participants analyzed at specified timepoints.","reportingStatus":"POSTED","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","timeFrame":"Month 7 to 24, Month 7 to 30, Month 7 to 40","groups":[{"id":"OG000","title":"Group 1: Ad26.Mos4.HIV + Clade C and Mosaic gp140","description":"Participants received adenovirus serotype 26.Mosaic 4.human immunodeficiency virus (Ad26.Mos4.HIV) 5\\*10\\^10 viral particles (vp) intramuscular (IM) injection into the deltoid muscle as a monotherapy at Months 0 (Day 1) and 3 (Day 84) (preferably the deltoid of the non-dominant upper arm) along with adjuvanted protein formulation consisting of Clade C protein 80 micrograms (mcg), Mosaic protein 75 mcg and adjuvanted aluminum phosphate 425 mcg, into the deltoid muscle at Months 6 (Day 168) and 12 (Day 364) (different deltoid for each injection)."},{"id":"OG001","title":"Group 2: Placebo","description":"Participants received placebo into the deltoid muscle at Months 0 (Day 1), 3 (Day 84; 1 injection), 6 (Day 168) and 12 (Day 364; 2 injections)."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"1525"},{"groupId":"OG001","value":"1494"}]}],"classes":[{"title":"Month 7 to 24: Latin America","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"1244"},{"groupId":"OG001","value":"1214"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"63"},{"groupId":"OG001","value":"54"}]}]},{"title":"Month 7 to 24: North America","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"74"},{"groupId":"OG001","value":"71"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"1"}]}]},{"title":"Month 7 to 24: Europe","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"207"},{"groupId":"OG001","value":"209"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"2"},{"groupId":"OG001","value":"3"}]}]},{"title":"Month 7 to 30: Latin America","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"1244"},{"groupId":"OG001","value":"1214"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"68"},{"groupId":"OG001","value":"63"}]}]},{"title":"Month 7 to 30: North America","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"74"},{"groupId":"OG001","value":"71"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"1"}]}]},{"title":"Month 7 to 30: Europe","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"207"},{"groupId":"OG001","value":"209"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"3"},{"groupId":"OG001","value":"3"}]}]},{"title":"Month 7 to 40: Latin America","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"1244"},{"groupId":"OG001","value":"1214"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"68"},{"groupId":"OG001","value":"64"}]}]},{"title":"Month 7 to 40: North America","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"74"},{"groupId":"OG001","value":"71"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"1"}]}]},{"title":"Month 7 to 40: Europe","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"207"},{"groupId":"OG001","value":"209"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"3"},{"groupId":"OG001","value":"3"}]}]}]},{"type":"SECONDARY","title":"Number of Participants With an HIV-1 Infection by Adenovirus Serotype 26 (Ad26) at Baseline","description":"Number of participants with an HIV-1 infection by Ad26 at baseline were reported.","populationDescription":"The immunogenicity analysis set included participants who acquired HIV-1 (case) and HIV-1 test negative (controls) that were selected for the case-control analysis. Here, 'N' (number of participants analyzed) indicates number of participants evaluable for this outcome measure.","reportingStatus":"POSTED","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","timeFrame":"Baseline (Day 1)","groups":[{"id":"OG000","title":"Group 1: Ad26.Mos4.HIV + Clade C and Mosaic gp140","description":"Participants received adenovirus serotype 26.Mosaic 4.human immunodeficiency virus (Ad26.Mos4.HIV) 5\\*10\\^10 viral particles (vp) intramuscular (IM) injection into the deltoid muscle as a monotherapy at Months 0 (Day 1) and 3 (Day 84) (preferably the deltoid of the non-dominant upper arm) along with adjuvanted protein formulation consisting of Clade C protein 80 micrograms (mcg), Mosaic protein 75 mcg and adjuvanted aluminum phosphate 425 mcg, into the deltoid muscle at Months 6 (Day 168) and 12 (Day 364) (different deltoid for each injection)."},{"id":"OG001","title":"Group 2: Placebo","description":"Participants received placebo into the deltoid muscle at Months 0 (Day 1), 3 (Day 84; 1 injection), 6 (Day 168) and 12 (Day 364; 2 injections)."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"364"},{"groupId":"OG001","value":"23"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"204"},{"groupId":"OG001","value":"10"}]}]}]},{"type":"SECONDARY","title":"Geometric Mean Antibody Titers For Adenovirus Serotype 26 (Ad26) as Determined by Vector Neutralization Assay (VNA)","description":"Geometric mean antibody titers for Ad26 as determined by VNA were reported.","populationDescription":"The immunogenicity analysis set included participants who acquired HIV-1 (case) and HIV-1 test negative (controls) that were selected for the analysis. Here, 'N' (number of participants analyzed) indicates number of participants evaluable for this outcome measure.","reportingStatus":"POSTED","paramType":"GEOMETRIC_MEAN","dispersionType":"95% Confidence Interval","unitOfMeasure":"Titers","timeFrame":"From Day 1 up to Month 40","groups":[{"id":"OG000","title":"Group 1: Ad26.Mos4.HIV + Clade C and Mosaic gp140","description":"Participants received adenovirus serotype 26.Mosaic 4.human immunodeficiency virus (Ad26.Mos4.HIV) 5\\*10\\^10 viral particles (vp) intramuscular (IM) injection into the deltoid muscle as a monotherapy at Months 0 (Day 1) and 3 (Day 84) (preferably the deltoid of the non-dominant upper arm) along with adjuvanted protein formulation consisting of Clade C protein 80 micrograms (mcg), Mosaic protein 75 mcg and adjuvanted aluminum phosphate 425 mcg, into the deltoid muscle at Months 6 (Day 168) and 12 (Day 364) (different deltoid for each injection)."},{"id":"OG001","title":"Group 2: Placebo","description":"Participants received placebo into the deltoid muscle at Months 0 (Day 1), 3 (Day 84; 1 injection), 6 (Day 168) and 12 (Day 364; 2 injections)."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"364"},{"groupId":"OG001","value":"23"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"66.6","spread":"54.1","lowerLimit":"54.1","upperLimit":"82.0"},{"groupId":"OG001","value":"41.3","spread":"16.1","lowerLimit":"16.1","upperLimit":"106.2"}]}]}]},{"type":"SECONDARY","title":"Number of Participants With HIV-1 Infection by Pre/Post-exposure Prophylaxis (P[r]EP) Use","description":"Number of participants with HIV-1 infection by P(r)EP use were reported. P(r)EP was assessed with a 4 item survey. Each item was measured on a scale ranging from 1 (strongly disagree) to 5 (strongly agree). Higher scores indicating higher levels of self-efficacy. If participant showed any evidence of P(r)EP use during the period based on questionnaire responses, concomitant medications or dried blood spot analysis, the response was \"yes\". The data represents the cumulative incidence of HIV-1 infections at specified intervals.","populationDescription":"The PP set included all subjects in FAS (all randomized participants who received at least one vaccine) set who had a negative HIV test 4 weeks post 3rd vaccination visit (that is, at Month 7 Visit) and who received all planned vaccinations at the first three vaccination visits within respective visit windows. Here, 'N' (number of participants analyzed) is number of participants evaluable for this outcome measure and 'n' (number analyzed) indicated participants analyzed at specified timepoints.","reportingStatus":"POSTED","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","timeFrame":"Month 7 to 24, Month 7 to 30, Month 7 to 40","groups":[{"id":"OG000","title":"Group 1: Ad26.Mos4.HIV + Clade C and Mosaic gp140","description":"Participants received adenovirus serotype 26.Mosaic 4.human immunodeficiency virus (Ad26.Mos4.HIV) 5\\*10\\^10 viral particles (vp) intramuscular (IM) injection into the deltoid muscle as a monotherapy at Months 0 (Day 1) and 3 (Day 84) (preferably the deltoid of the non-dominant upper arm) along with adjuvanted protein formulation consisting of Clade C protein 80 micrograms (mcg), Mosaic protein 75 mcg and adjuvanted aluminum phosphate 425 mcg, into the deltoid muscle at Months 6 (Day 168) and 12 (Day 364) (different deltoid for each injection)."},{"id":"OG001","title":"Group 2: Placebo","description":"Participants received placebo into the deltoid muscle at Months 0 (Day 1), 3 (Day 84; 1 injection), 6 (Day 168) and 12 (Day 364; 2 injections)."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"1525"},{"groupId":"OG001","value":"1494"}]}],"classes":[{"title":"Month 7 to 24: P(r)EP Use=Y","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"335"},{"groupId":"OG001","value":"359"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"5"},{"groupId":"OG001","value":"3"}]}]},{"title":"Month 7 to 24: P(r)EP Use=N","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"1190"},{"groupId":"OG001","value":"1135"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"60"},{"groupId":"OG001","value":"55"}]}]},{"title":"Month 7 to 30: P(r)EP Use=Y","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"355"},{"groupId":"OG001","value":"371"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"5"},{"groupId":"OG001","value":"5"}]}]},{"title":"Month 7 to 30: P(r)EP Use=N","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"1170"},{"groupId":"OG001","value":"1123"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"66"},{"groupId":"OG001","value":"62"}]}]},{"title":"Month 7 to 40: P(r)EP Use=Y","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"355"},{"groupId":"OG001","value":"372"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"5"},{"groupId":"OG001","value":"5"}]}]},{"title":"Month 7 to 40: P(r)EP Use=N","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"1170"},{"groupId":"OG001","value":"1122"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"66"},{"groupId":"OG001","value":"63"}]}]}]}]},"adverseEventsModule":{"frequencyThreshold":"1","timeFrame":"Unsolicited AEs: 28 days after each vaccination (up to Day 392); Solicited AEs: 7 days after each vaccination (up to Day 371); All-cause mortality and SAE: From Day 1 up to Month 40","description":"The full analysis set (FAS) set included all randomized participants who received at least one vaccine administration.","eventGroups":[{"id":"EG000","title":"Group 1: Ad26.Mos4.HIV + Clade C and Mosaic gp140","description":"Participants received adenovirus serotype 26.Mosaic 4.human immunodeficiency virus (Ad26.Mos4.HIV) 5\\*10\\^10 viral particles (vp) intramuscular (IM) injection into the deltoid muscle as a monotherapy at Months 0 (Day 1) and 3 (Day 84) (preferably the deltoid of the non-dominant upper arm) along with adjuvanted protein formulation consisting of Clade C protein 80 micrograms (mcg), Mosaic protein 75 mcg and adjuvanted aluminum phosphate 425 mcg, into the deltoid muscle at Months 6 (Day 168) and 12 (Day 364) (different deltoid for each injection).","deathsNumAffected":4,"deathsNumAtRisk":1942,"seriousNumAffected":82,"seriousNumAtRisk":1942,"otherNumAffected":1687,"otherNumAtRisk":1942},{"id":"EG001","title":"Group 2: Placebo","description":"Participants received placebo into the deltoid muscle at Months 0 (Day 1), 3 (Day 84; 1 injection), 6 (Day 168) and 12 (Day 364; 2 injections).","deathsNumAffected":6,"deathsNumAtRisk":1945,"seriousNumAffected":77,"seriousNumAtRisk":1945,"otherNumAffected":1348,"otherNumAtRisk":1945}],"seriousEvents":[{"term":"Anaemia","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":1942},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":1945}]},{"term":"Coagulopathy","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":1942},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":1945}]},{"term":"Lymphadenitis","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":1942},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":1945}]},{"term":"Angina Pectoris","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":1942},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":1945}]},{"term":"Cardiac Arrest","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":1942},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":1945}]},{"term":"Myocardial Infarction","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":1942},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":1945}]},{"term":"Myocardial Ischaemia","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":1942},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":1945}]},{"term":"Pericarditis","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":1942},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":1945}]},{"term":"Alcoholic Pancreatitis","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":1942},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":1945}]},{"term":"Anal Fistula","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":1942},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":1945}]},{"term":"Diarrhoea","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":1942},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":1945}]},{"term":"Haemorrhoids","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":1942},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":1945}]},{"term":"Ileal Perforation","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":1942},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":1945}]},{"term":"Incarcerated Umbilical Hernia","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":1942},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":1945}]},{"term":"Inguinal Hernia","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":1942},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":1945}]},{"term":"Intestinal Obstruction","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":1942},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":1945}]},{"term":"Intestinal Perforation","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":1942},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":1945}]},{"term":"Intussusception","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":1942},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":1945}]},{"term":"Oedematous Pancreatitis","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":1942},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":1945}]},{"term":"Death","organSystem":"General disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":1942},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":1945}]},{"term":"Cholecystitis","organSystem":"Hepatobiliary disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":1942},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":1945}]},{"term":"Cholecystitis Acute","organSystem":"Hepatobiliary disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":1942},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":1945}]},{"term":"Cholelithiasis","organSystem":"Hepatobiliary disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":1942},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":1945}]},{"term":"Hepatitis","organSystem":"Hepatobiliary disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":1942},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":1945}]},{"term":"Abdominal Sepsis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 26.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":1942},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":1945}]},{"term":"Abscess Jaw","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 26.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":1942},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":1945}]},{"term":"Abscess Limb","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 26.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":1942},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":1945}]},{"term":"Acute HIV Infection","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 26.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":1942},{"groupId":"EG001","numEvents":3,"numAffected":1,"numAtRisk":1945}]},{"term":"Acute Hepatitis C","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 26.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":1942},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":1945}]},{"term":"Appendicitis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 26.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":8,"numAffected":8,"numAtRisk":1942},{"groupId":"EG001","numEvents":11,"numAffected":11,"numAtRisk":1945}]},{"term":"Bacterial Colitis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 26.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":1942},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":1945}]},{"term":"COVID-19","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 26.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":5,"numAffected":5,"numAtRisk":1942},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":1945}]},{"term":"COVID-19 Pneumonia","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 26.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":1942},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":1945}]},{"term":"Cellulitis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 26.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":1942},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":1945}]},{"term":"Complicated Appendicitis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 26.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":1942},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":1945}]},{"term":"Conjunctivitis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 26.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":1942},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":1945}]},{"term":"Dengue Fever","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 26.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":1942},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":1945}]},{"term":"Fournier's Gangrene","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 26.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":1942},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":1945}]},{"term":"Gastroenteritis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 26.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":3,"numAffected":3,"numAtRisk":1942},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":1945}]},{"term":"Helicobacter Sepsis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 26.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":1942},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":1945}]},{"term":"Hepatitis A","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 26.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":1942},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":1945}]},{"term":"Influenza","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 26.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":1942},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":1945}]},{"term":"Meningitis Tuberculous","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 26.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":1942},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":1945}]},{"term":"Meningitis Viral","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 26.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":1942},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":1945}]},{"term":"Monkeypox","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 26.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":1942},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":1945}]},{"term":"Neurosyphilis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 26.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":3,"numAffected":3,"numAtRisk":1942},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":1945}]},{"term":"Osteomyelitis Chronic","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 26.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":1942},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":1945}]},{"term":"Peritonsillar Abscess","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 26.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":1942},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":1945}]},{"term":"Pneumonia","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 26.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":3,"numAffected":3,"numAtRisk":1942},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":1945}]},{"term":"Pulmonary Sepsis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 26.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":3,"numAffected":3,"numAtRisk":1942},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":1945}]},{"term":"Pulmonary Tuberculosis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 26.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":1942},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":1945}]},{"term":"Pyelonephritis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 26.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":1942},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":1945}]},{"term":"Pyelonephritis Acute","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 26.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":1942},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":1945}]},{"term":"Septic Shock","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 26.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":1942},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":1945}]},{"term":"Soft Tissue Infection","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 26.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":1942},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":1945}]},{"term":"Subcutaneous Abscess","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 26.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":1942},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":1945}]},{"term":"Tonsillitis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 26.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":1942},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":1945}]},{"term":"Urinary Tract Infection","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 26.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":1942},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":1945}]},{"term":"Clavicle Fracture","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 26.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":1942},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":1945}]},{"term":"Contusion","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 26.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":1942},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":1945}]},{"term":"Craniocerebral Injury","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 26.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":1942},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":1945}]},{"term":"Facial Bones Fracture","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 26.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":1942},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":1945}]},{"term":"Femur Fracture","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 26.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":1942},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":1945}]},{"term":"Foot Fracture","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 26.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":1942},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":1945}]},{"term":"Hand Fracture","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 26.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":1942},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":1945}]},{"term":"Humerus Fracture","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 26.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":1942},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":1945}]},{"term":"Injury","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 26.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":1942},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":1945}]},{"term":"Joint Dislocation","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 26.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":1,"numAtRisk":1942},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":1945}]},{"term":"Joint Injury","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 26.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":1942},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":1945}]},{"term":"Ligament Rupture","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 26.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":1942},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":1945}]},{"term":"Lower Limb Fracture","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 26.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":1942},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":1945}]},{"term":"Multiple Injuries","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 26.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":1942},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":1945}]},{"term":"Pneumothorax Traumatic","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 26.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":1942},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":1945}]},{"term":"Post-Traumatic Pain","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 26.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":1942},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":1945}]},{"term":"Radius Fracture","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 26.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":1942},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":1945}]},{"term":"Thermal Burn","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 26.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":1942},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":1945}]},{"term":"Toxicity to Various Agents","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 26.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":1942},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":1945}]},{"term":"Traumatic Fracture","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 26.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":1942},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":1945}]},{"term":"Traumatic Intracranial Haemorrhage","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 26.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":1942},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":1945}]},{"term":"Traumatic Lung Injury","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 26.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":1942},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":1945}]},{"term":"Wrist Fracture","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 26.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":1942},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":1945}]},{"term":"Blood Creatine Phosphokinase Increased","organSystem":"Investigations","sourceVocabulary":"MedDRA 26.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":1942},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":1945}]},{"term":"Diabetic Metabolic Decompensation","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":1942},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":1945}]},{"term":"Facial Asymmetry","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":1942},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":1945}]},{"term":"Intervertebral Disc Protrusion","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":3,"numAffected":3,"numAtRisk":1942},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":1945}]},{"term":"Muscular Weakness","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":1942},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":1945}]},{"term":"Rhabdomyolysis","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":1942},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":1945}]},{"term":"Bone Neoplasm","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"MedDRA 26.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":1942},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":1945}]},{"term":"Cholangiocarcinoma","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"MedDRA 26.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":1942},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":1945}]},{"term":"Head and Neck Cancer","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"MedDRA 26.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":1942},{"groupId":"EG001","numEvents":2,"numAffected":1,"numAtRisk":1945}]},{"term":"Non-Hodgkin's Lymphoma","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"MedDRA 26.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":1942},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":1945}]},{"term":"T-Cell Type Acute Leukaemia","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"MedDRA 26.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":1942},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":1945}]},{"term":"Testicular Seminoma (Pure)","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"MedDRA 26.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":1942},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":1945}]},{"term":"Cerebral Haemorrhage","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":1942},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":1945}]},{"term":"Nerve Compression","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":1942},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":1945}]},{"term":"Syncope","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":1942},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":1945}]},{"term":"Patient-Device Incompatibility","organSystem":"Product Issues","sourceVocabulary":"MedDRA 26.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":1942},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":1945}]},{"term":"Alcohol Withdrawal Syndrome","organSystem":"Psychiatric disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":1942},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":1945}]},{"term":"Anxiety","organSystem":"Psychiatric disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":1942},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":1945}]},{"term":"Behaviour Disorder","organSystem":"Psychiatric disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":1942},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":1945}]},{"term":"Bipolar Disorder","organSystem":"Psychiatric disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":1942},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":1945}]},{"term":"Completed Suicide","organSystem":"Psychiatric disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":1942},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":1945}]},{"term":"Depression","organSystem":"Psychiatric disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":1942},{"groupId":"EG001","numEvents":2,"numAffected":1,"numAtRisk":1945}]},{"term":"Depression Suicidal","organSystem":"Psychiatric disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":1942},{"groupId":"EG001","numEvents":2,"numAffected":1,"numAtRisk":1945}]},{"term":"Drug Abuse","organSystem":"Psychiatric disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":1942},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":1945}]},{"term":"Drug Use Disorder","organSystem":"Psychiatric disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":1942},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":1945}]},{"term":"Generalised Anxiety Disorder","organSystem":"Psychiatric disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":1942},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":1945}]},{"term":"Intentional Self-Injury","organSystem":"Psychiatric disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":1942},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":1945}]},{"term":"Mania","organSystem":"Psychiatric disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":1942},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":1945}]},{"term":"Mental Disorder","organSystem":"Psychiatric disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":1942},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":1945}]},{"term":"Suicidal Ideation","organSystem":"Psychiatric disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":1942},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":1945}]},{"term":"Suicide Attempt","organSystem":"Psychiatric disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":4,"numAffected":4,"numAtRisk":1942},{"groupId":"EG001","numEvents":7,"numAffected":6,"numAtRisk":1945}]},{"term":"Acute Kidney Injury","organSystem":"Renal and urinary disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":1942},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":1945}]},{"term":"Calculus Urinary","organSystem":"Renal and urinary disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":1942},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":1945}]},{"term":"Nephrolithiasis","organSystem":"Renal and urinary disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":1942},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":1945}]},{"term":"Renal Failure","organSystem":"Renal and urinary disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":1942},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":1945}]},{"term":"Urinary Tract Obstruction","organSystem":"Renal and urinary disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":1942},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":1945}]},{"term":"Acute Respiratory Failure","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":1942},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":1945}]},{"term":"Asphyxia","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":1942},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":1945}]},{"term":"Nasal Septum Deviation","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":1942},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":1945}]},{"term":"Pleural Effusion","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":1942},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":1945}]},{"term":"Pneumothorax","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":1942},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":1945}]},{"term":"Pneumothorax Spontaneous","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":1942},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":1945}]},{"term":"Pulmonary Embolism","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":1942},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":1945}]},{"term":"Cellulite","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":1942},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":1945}]},{"term":"Nasal Septal Operation","organSystem":"Surgical and medical procedures","sourceVocabulary":"MedDRA 26.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":1942},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":1945}]},{"term":"Haematoma","organSystem":"Vascular disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":1942},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":1945}]},{"term":"Peripheral Venous Disease","organSystem":"Vascular disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":1942},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":1945}]}],"otherEvents":[{"term":"Diarrhoea","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":60,"numAffected":51,"numAtRisk":1942},{"groupId":"EG001","numEvents":61,"numAffected":54,"numAtRisk":1945}]},{"term":"Nausea (Solicited)","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":758,"numAffected":520,"numAtRisk":1942},{"groupId":"EG001","numEvents":552,"numAffected":361,"numAtRisk":1945}]},{"term":"Vomiting (Solicited)","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":154,"numAffected":128,"numAtRisk":1942},{"groupId":"EG001","numEvents":115,"numAffected":85,"numAtRisk":1945}]},{"term":"Chills (Solicited)","organSystem":"General disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1405,"numAffected":857,"numAtRisk":1942},{"groupId":"EG001","numEvents":533,"numAffected":342,"numAtRisk":1945}]},{"term":"Fatigue (Solicited)","organSystem":"General disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":3376,"numAffected":1323,"numAtRisk":1942},{"groupId":"EG001","numEvents":2018,"numAffected":928,"numAtRisk":1945}]},{"term":"Pyrexia (Solicited)","organSystem":"General disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":508,"numAffected":400,"numAtRisk":1942},{"groupId":"EG001","numEvents":174,"numAffected":137,"numAtRisk":1945}]},{"term":"Vaccination Site Erythema (Solicited)","organSystem":"General disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":66,"numAffected":47,"numAtRisk":1942},{"groupId":"EG001","numEvents":7,"numAffected":7,"numAtRisk":1945}]},{"term":"Vaccination Site Pain (Solicited)","organSystem":"General disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":5543,"numAffected":1519,"numAtRisk":1942},{"groupId":"EG001","numEvents":1521,"numAffected":695,"numAtRisk":1945}]},{"term":"Vaccination Site Swelling (Solicited)","organSystem":"General disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":144,"numAffected":89,"numAtRisk":1942},{"groupId":"EG001","numEvents":10,"numAffected":9,"numAtRisk":1945}]},{"term":"Anal Chlamydia Infection","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 26.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":22,"numAffected":22,"numAtRisk":1942},{"groupId":"EG001","numEvents":39,"numAffected":39,"numAtRisk":1945}]},{"term":"COVID-19","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 26.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":76,"numAffected":75,"numAtRisk":1942},{"groupId":"EG001","numEvents":81,"numAffected":79,"numAtRisk":1945}]},{"term":"Gastroenteritis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 26.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":16,"numAffected":16,"numAtRisk":1942},{"groupId":"EG001","numEvents":23,"numAffected":23,"numAtRisk":1945}]},{"term":"Influenza","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 26.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":35,"numAffected":34,"numAtRisk":1942},{"groupId":"EG001","numEvents":38,"numAffected":34,"numAtRisk":1945}]},{"term":"Nasopharyngitis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 26.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":25,"numAffected":25,"numAtRisk":1942},{"groupId":"EG001","numEvents":29,"numAffected":28,"numAtRisk":1945}]},{"term":"Oropharyngeal Gonococcal Infection","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 26.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":28,"numAffected":27,"numAtRisk":1942},{"groupId":"EG001","numEvents":43,"numAffected":40,"numAtRisk":1945}]},{"term":"Pharyngitis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 26.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":22,"numAffected":20,"numAtRisk":1942},{"groupId":"EG001","numEvents":21,"numAffected":20,"numAtRisk":1945}]},{"term":"Proctitis Gonococcal","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 26.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":33,"numAffected":33,"numAtRisk":1942},{"groupId":"EG001","numEvents":33,"numAffected":32,"numAtRisk":1945}]},{"term":"Syphilis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 26.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":25,"numAffected":24,"numAtRisk":1942},{"groupId":"EG001","numEvents":41,"numAffected":40,"numAtRisk":1945}]},{"term":"Upper Respiratory Tract Infection","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 26.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":31,"numAffected":29,"numAtRisk":1942},{"groupId":"EG001","numEvents":28,"numAffected":27,"numAtRisk":1945}]},{"term":"Arthralgia (Solicited)","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1503,"numAffected":806,"numAtRisk":1942},{"groupId":"EG001","numEvents":639,"numAffected":380,"numAtRisk":1945}]},{"term":"Myalgia (Solicited)","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2333,"numAffected":1124,"numAtRisk":1942},{"groupId":"EG001","numEvents":991,"numAffected":563,"numAtRisk":1945}]},{"term":"Headache (Solicited)","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2550,"numAffected":1181,"numAtRisk":1942},{"groupId":"EG001","numEvents":1834,"numAffected":863,"numAtRisk":1945}]},{"term":"Hypertension","organSystem":"Vascular disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":18,"numAffected":17,"numAtRisk":1942},{"groupId":"EG001","numEvents":25,"numAffected":24,"numAtRisk":1945}]}]},"moreInfoModule":{"certainAgreement":{"piSponsorEmployee":false,"restrictionType":"OTHER","restrictiveAgreement":true,"otherDetails":"If an investigator wishes to publish information from the study, a copy of the manuscript must be provided to the sponsor and its partners for review at least 21 days before submission for publication or presentation. At the request of the sponsor and/or partners, such submission may be delayed up to 60 days. If requested by the sponsor in writing, the investigator will withhold such publication for up to an additional 60 days to allow for filing of a patent application."},"pointOfContact":{"title":"Medical Leader","organization":"Janssen Vaccines & Prevention B.V.","email":"ClinicalTrialDisclosure@its.jnj.com","phone":"844-434-4210"}}},"documentSection":{"largeDocumentModule":{"largeDocs":[{"typeAbbrev":"Prot","hasProtocol":true,"hasSap":false,"hasIcf":false,"label":"Study Protocol","date":"2023-02-28","uploadDate":"2024-07-04T03:41","filename":"Prot_000.pdf","size":2671435},{"typeAbbrev":"SAP","hasProtocol":false,"hasSap":true,"hasIcf":false,"label":"Statistical Analysis Plan","date":"2024-03-05","uploadDate":"2024-07-04T03:41","filename":"SAP_001.pdf","size":1537159}]}},"derivedSection":{"miscInfoModule":{"versionHolder":"2026-11-09"}},"hasResults":true}